|
Jul 17
|
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
|
|
Jul 17
|
GenSight Biologics Announces an Additional Financing Amounting to Approximately EUR 500,000 from Existing Shareholder
|
|
Jul 1
|
GenSight Biologics Announces Successful Completion of a Private Placement of Close to EUR 4 Million
|
|
Jun 26
|
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
|
|
Apr 23
|
GenSight Biologics Annual General Meeting on May 13, 2025
|
|
Feb 12
|
GenSight’s Optic Neuropathy gene therapy sustains efficacy over five years
|
|
Feb 12
|
GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study
|